share_log

V2X, INC. ANNOUNCES PROPOSED SECONDARY OFFERING OF COMMON STOCK

V2X, INC. ANNOUNCES PROPOSED SECONDARY OFFERING OF COMMON STOCK

V2X公司宣佈擬議的普通股次級發行
PR Newswire ·  09/05 04:04

MCLEAN, Va., Sept. 4, 2024 /PRNewswire/ -- V2X, Inc. (NYSE: VVX) ("V2X" or the "company"), a leading provider of global mission solutions, announced today the commencement of an underwritten public offering of 2,000,000 shares of common stock by a certain selling stockholder. In connection with the offering, the selling stockholder intends to grant the underwriters an option to purchase up to 300,000 additional shares of common stock from the selling stockholder. V2X is not selling any shares of common stock in the offering, and V2X will not receive any proceeds from the offering by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

2024年9月4日,弗吉尼亞州麥克萊恩 – 全球任務解決方案領先提供商V2X公司(紐約證券交易所:VVX)("V2X" 或 "公司"),今日宣佈由特定售股股東進行200萬股普通股的公開發行。與此同時,售股股東打算授予承銷商購買多達30萬股普通股的選擇權。V2X公司不會在此次發行中出售任何普通股,也不會從售股股東的發行中獲得任何收益。擬議的發行取決於市場和其他條件,不能保證發行是否會完成,或者發行的實際規模或條款。

Goldman Sachs & Co. LLC, Morgan Stanley and Baird are serving as joint book-running managers for the proposed offering.

高盛、摩根士丹利和貝爾德將作爲擬議發行的聯席主承銷商。

A registration statement on Form S-3 (File No. 333-267223) relating to the shares of common stock of V2X to be sold in the proposed offering was declared effective by the Securities and Exchange Commission (the "SEC") on September 12, 2022. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering have been filed with the SEC and may be obtained by visiting EDGAR on the SEC's website at www.sec.gov or by contacting Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282-2198, Attention: Prospectus Department, Telephone: 866-471-2526, Email: [email protected], Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department, or Baird, 777 East Wisconsin Avenue, Milwaukee, WI 53202, Attention: Syndicate Department, Telephone: 800-792-2473, Email: [email protected]. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

V2X公司普通股擬議發行的相關注冊聲明(文件編號 333-267223)於2022年9月12日被美國證券交易委員會("SEC")宣佈生效。與擬議發行相關的初步招股說明書和附屬招股說明書已在SEC登記處進行了備案,並可通過訪問SEC網站上的EDGAR或聯繫高盛和摩根士丹利以及貝爾德獲取。擬議發行的最終條款將在提交給SEC的最終招股說明書中披露。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Tonix Pharmaceuticals Holding Corp.*,是一家完全整合的生物製藥公司,致力於發展富有創新性的治療和預防潛在疾病的製劑。公司正在研發針對纖維肌痛患者的產品TNX-102 SL,已經完成了兩項具有統計學意義的3期研究。TNX-102 SL也正在被開發用於治療急性壓力反應以及類纖維肌痛的長期COVID。Tonix的神經系統藥物組合包括TNX-1300(可卡因酯酶),這是一種用於治療可卡因中毒、被授予「突破性療法」稱號的生物製品。Tonix的免疫學研發組合包括生物製品,用於治療器官移植排斥、自身免疫和癌症,包括TNX-1500,這是一種人源單克隆抗體,靶向CD40L(CD40L或CD154)用於預防異體移植器官排斥並用於治療自身免疫性疾病。Tonix在罕見疾病和傳染病領域的正在研發中的產品。商業子公司Tonix Medicines市場上銷售Zembrace SymTouch(舒馬曲坦注射液)3毫克和Tosymra(舒馬曲坦鼻噴劑)10毫克,用於成年急性偏頭疼的治療。

Forward-Looking Statements

前瞻性聲明

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and the Private Securities Litigation Reform Act of 1995 and, as such, may involve risks and uncertainties. All statements included in this press release, other than statements that are purely historical, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "could," "potential," "continue" or similar terminology. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements.

本新聞稿包含根據修正後的1934年證券交易法第21E條和1933年證券法第27A條,以及1995年《私人證券訴訟改革法》,屬於前瞻性聲明,並且可能涉及風險和不確定性。本新聞稿中包含的所有聲明,除了純粹歷史性的聲明之外,都屬於前瞻性聲明。前瞻性聲明通常可以通過使用「可能」、「將」、「期望」、「打算」、「估計」、「預期」、「相信」、「可能」、「繼續」或類似的術語來識別。這些前瞻性聲明並非對未來業績的保證,並且可能面臨可能導致實際結果與前瞻性聲明所 contemplat的結果有實質不同的風險和不確定性。

These risks and uncertainties include, but are not limited to: the company's ability to submit proposals for and/or win all potential opportunities in their pipeline; the company's ability to retain and renew existing contracts; the company's ability to compete with other companies in their market; security breaches, cyber-attacks or cyber intrusions, and other disruptions to their information technology and operation; their mix of cost-plus, cost-reimbursable, firm-fixed-price and time-and-materials contracts; maintaining their reputation and relationship with the U.S. government; protests of new awards; economic, political and social conditions in the countries in which they conduct their business; changes in U.S. or international government defense budgets; government regulations and compliance therewith, including changes to the Department of Defense procurement process; changes in technology; the company's ability to protect their intellectual property rights; governmental investigations, reviews, audits and cost adjustments; contingencies related to actual or alleged environmental contamination, claims and concerns; delays in completion of the U.S. government budget; the company's success in extending, deepening, and enhancing their technical capabilities; the company's success in expanding their geographic footprint or broadening their customer base; the company's ability to realize the full amounts reflected in their backlog; impairment of goodwill; misconduct of the company's employees, subcontractors, agents, prime contractors and business partners; the company's ability to control costs; the company's level of indebtedness; terms of the company's credit agreements; inflation and interest rate risk; geopolitical risk, including as a result of recent global hostilities; the company's subcontractors' performance; economic and capital markets conditions; the company's ability to maintain safe work sites and equipment; the company's ability to retain and recruit qualified personnel; the company's ability to maintain good relationships with their workforce; the company's teaming relationships with other contractors; changes in the company's accounting estimates; the adequacy of the company's insurance coverage; volatility in the company's stock price; changes in the company's tax provisions or exposure to additional income tax liabilities; risks and uncertainties relating to integrating and refining internal control systems post-merger; changes in generally accepted accounting principles; and other factors described in the company's reports filed on Form 10-K, 10-Q and 8-K, and other filings the company files with the SEC from time to time. V2X undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

這些風險和不確定性包括但不限於:公司能否提交提案並/或贏得其管道中的所有潛在機會;公司能否保留和續約現有合同;公司能否與其市場上的其他公司競爭;安全漏洞、網絡攻擊或網絡入侵和對其信息技術和運營的其他干擾;成本加成、成本報銷、固定價格和時間與材料合同的混合;保持其與美國政府的聲譽和關係;新獎項的抗議;公司在開展業務的國家的經濟、政治和社會狀況;美國或國際政府國防預算的變化;政府法規和其依從性,包括國防部採購流程的變化;技術變化;公司能否保護其知識產權;政府調查、審查、審計和成本調整;實際或被指控的環境污染、索賠和顧慮的待定事項;美國政府預算完成的延期;公司擴展、加深和增強其技術能力的成功;公司擴大地理範圍或拓寬客戶基礎的成功;公司是否能夠實現其積壓工作中反映的全部金額;商譽減值;公司員工、分包商、代理商、總承包商和業務夥伴的不當行爲;公司控制成本的能力;公司的負債水平;公司信貸協議條款;通貨膨脹和利率風險;地緣政治風險,包括最近的全球敵意的結果;公司分包商的表現;經濟和資本市場條件;公司能否維護安全的工作場所和設備;公司能否留住和招聘合格人員;公司是否能夠與其勞動力保持良好關係;公司與其他承包商的合作關係;公司會計估計的變化;公司的保險覆蓋的充分性;公司股價的波動性;公司稅務規定的變化或額外所得稅責任的暴露;與合併後整合和完善內部控制系統有關的風險和不確定性;普遍公認的會計原則的變化;以及公司不時向證監會提交的10-K、10-Q和8-K報告中描述的其他因素。V2X不承擔更新任何前瞻性聲明的義務,除非法律要求。

V2X, Inc.
Mike Smith
Vice President, Treasury, Corporate Development and Investor Relations
1-719-637-5773
[email protected]

V2X,公司
邁克·史密斯
財務副總裁、公司發展與投資者關係
1-719-637-5773
[email protected]

SOURCE V2X, Inc.

V2X公司消息來源

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論